Back to top
more

Cencora, Inc. (COR)

(Delayed Data from NYSE)

$234.70 USD

234.70
1,011,843

+2.17 (0.93%)

Updated Jun 17, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Labcorp (LH) to Boost Clinical Diagnostics With New Deal

by Zacks Equity Research

The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.

Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression

by Zacks Equity Research

Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.

Here's Why Cencora (COR) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Investors Should Hold Teladoc (TDOC) Stock Now

by Zacks Equity Research

Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Walgreens Boots (WBA) Q2 Earnings Top Estimates, EPS View Down

by Zacks Equity Research

Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal second quarter benefited from higher branded drug inflation and strong execution in pharmacy services.

GE HealthCare's (GEHC) PVA to Aid in Capturing Prostate Volume

by Zacks Equity Research

GE HealthCare (GEHC) announces the launch of Prostate Volume Assist AI-enabled urology software feature, which is likely to boost prostate imaging, capture prostate volume and increase workflow.

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on strong Healthcare business performance and raised 2024 guidance.

Are Medical Stocks Lagging Artivion (AORT) This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.

Zacks.com featured highlights include General Motors, Cardinal Health, Cencora, Alta Equipment Group and Asbury Automotive

by Zacks Equity Research

General Motors, Cardinal Health, Cencora, Alta Equipment Group and Asbury Automotive are part of the Zacks Screen of the Week article.

Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment

by Zacks Equity Research

Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.

Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark

by Zacks Equity Research

Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.

Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH), led by expansion in the knee business and recovery across the business.

DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about DexCom's (DXCM) strong product portfolio.

Stryker's (SYK) Latest Launch to Streamline Procedural Workflows

by Zacks Equity Research

Stryker's (SYK) latest addition to its Gamma legacy is expected to streamline workflows and enhance usability.

Why Cencora (COR) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Maharathi Basu headshot

5 Broker-Loved Stocks That Hold Promise Despite Volatility

by Maharathi Basu

We believe that stocks like General Motors (GM), Cardinal Health (CAH), Cencora (COR), Alta Equipment (ALTG) and Asbury (ABG) should be on an investor's watchlist.

Reasons to Add Cencora (COR) Stock in Your Portfolio Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Three Reasons to Retain Avantor (AVTR) Stock in Your Portfolio

by Zacks Equity Research

Avantor's (AVTR) strong product portfolio raises optimism about the stock.

Veeva Systems' (VEEV) Vault EDC Witnesses Increasing Adoption

by Zacks Equity Research

Veeva Systems' (VEEV) Vault EDC is likely to enable companies to build a modern clinical data foundation.

Reasons to Add Veeva Systems (VEEV) to Your Portfolio Now

by Zacks Equity Research

Veeva's strong product demand and strategic deals raise optimism about the stock.

GE HealthCare (GEHC) to Sell IONIC's FDA-Cleared nCommand Lite

by Zacks Equity Research

GE HealthCare (GEHC) announces the FDA approval of IONIC Health's nCommand Lite technology, which it will distribute for multi-vendor, multi-modality remote operations purposes exclusively.

QIAGEN (QGEN) Unveils QIAstat-Dx Analyzer With Remote Access

by Zacks Equity Research

With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.

Santanu Roy headshot

Beat the Market the Zacks Way: Micron Technology, American Eagle Outfitters, Cencora in Focus

by Santanu Roy

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.